+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Glycobiology Market- Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4591275
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Agilent Technologies
  • Bruker Corporation
  • Danaher Corporation
  • Merck Kgaa
  • New England Biolabs
  • Prozyme
  • MORE
The glycobiology market will show rapid growth due to the increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies.
  • The major pharmaceutical and biotech companies are heavily investing in the research and development of superior biological products, such as glycobiology products and products related to proteomics.
  • There is also an increased demand for curative treatments for many life-threatening diseases, such as cancer, which is expected to drive the pace of pharmaceutical and biotechnological R&D, as well as overall investments made in glycobiology field. This makes glycobiology an attractive option for big pharma and biotech companies to invest in. Furthermore, glycomic biomarkers have significant applications in drug development and diagnostics for many diseases.
  • In addition, a huge amount of investment is put into the development of its products and the approval of drugs that are developed, require a lot of regulatory stages that are necessary for the process. This, in turn, renders these products very expensive.
Key Market Trends

Drug Discovery and Development is Expected to be the Largest Growing Segment

On the basis of application, drug discovery and development has been accounted for the largest market share. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. There is an increasing R&D investments by pharmaceutical companies, which increases the drug discovery and development of glycomics. For instance, R&D expenditure of Merck accounted for USD 9.8 billion, in 2018.

The other applications segment is anticipated to witness the high CAGR due to rising clinical trials and R&D expenses incurred by key companies for research.

North America is Found Leading the Glycobiology Market

North America has been accounted for the largest market share due to the presence of key pharmaceutical and biopharmaceutical companies. The presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, there is also increasing applications of glycans in various cancers and increasing funds from the government in enhancing the field of glycobioogy, that helps the market to grow over the forecast period.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies undertaken by these companies for sustainable growth.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • Agilent Technologies
  • Bruker Corporation
  • Danaher Corporation
  • Merck Kgaa
  • New England Biolabs
  • Prozyme
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
4.2.2 Growing R&D Expenditure by Pharmaceutical and
Biotechnology Companies
4.3 Market Restraints
4.3.1 High Product Cost
4.3.2 Low Availability of Skilled Professionals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 By Product
5.1.1 Enzymes
5.1.2 Instruments
5.1.3 Kits
5.1.4 Reagents
5.2 By Application
5.2.1 Diagnostics
5.2.2 Drug Discovery and Development
5.2.3 Oncology
5.2.4 Immunology
5.2.5 Other Applications
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Contract Research Organizations
5.3.3 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Bruker Corporation
6.1.3 Danaher Corporation
6.1.4 Merck KGaA
6.1.5 New England Biolabs
6.1.6 ProZyme
6.1.7 Shimadzu Corporation
6.1.8 Takara Bio
6.1.9 Thermo Fisher Scientific
6.1.10 Waters Corporation

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Agilent Technologies
  • Bruker Corporation
  • Danaher Corporation
  • Merck KGaA
  • New England Biolabs
  • ProZyme
  • Shimadzu Corporation
  • Takara Bio
  • Thermo Fisher Scientific
  • Waters Corporation
Note: Product cover images may vary from those shown
5 of 5